Breast Cancer Clinical Trials in Dallas

Showing 321-340 of 593 trials

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

NCT03200704

This is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures as confirmed by Technitium99m (Tc99m) and Gamma Probe.

Breast CancerLymph Node MappingSentinel Lymph Node Biopsy

Novadaq Technologies ULC, now a part of Stryker152 participantsStarted Jan 2019

Scottsdale, Arizona, United States • Washington D.C., District of Columbia, United States • Jacksonville, Florida, United States +4 more locations

COMPLETEDPhase 2< 1 mile

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080

This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.

Triple Negative Breast Cancer

Baylor Research Institute10 participantsStarted Sep 2019

Dallas, Texas, United States

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Breast Cancer Trials in Other Cities

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

OA for Breast Cancer NAC Response

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

TAC Versus TC for Adjuvant Breast Cancer

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Investigation of Novel Surgical Imaging for Tumor Excision

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer

Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study

Other Conditions in Dallas